Sign In

Saturday, May 06, 2017 - 8:00 am to Tuesday, May 09, 2017 - 5:30 pm
Add to Calendar

Digestive Disease Week® 2017

McCormick Place
Chicago, IL

Digestive Disease Week® (DDW) is one of the largest meetings for the GI professional and attracts 15,000 physicians, researchers and academicians each year. At DDW you'll learn about new developments in your field, attend high-quality educational programs, and network with colleagues.

The AASLD Meeting at DDW 2017 will provide a forum for the exchange of groundbreaking research and clinical information in diseases of the liver and biliary tract and in liver transplantation. This will be done in a variety of formats, including plenary and parallel sessions, courses, workshops, and state-of-the-art lectures.

The Marriott Magnificent Mile will be the Headquarter Hotel for DDW.

DDW is co-sponsored by AASLD, AGA, ASGE, and SSAT.

AASLD Programming

For further information about AASLD and other programming, please visit Digestive Disease Week®.

Hepatology Update: The Year in Review

Saturday, May 6, 2 pm –5 pm
Moderators: Paul Martin, MD, FAASLD and Hugo E. Vargas, MD, FAASLD 

The primary goal of this program is to provide a comprehensive overview of recent advances in hepatology, focusing on major advances in the preceding 12 months. Particular emphasis will be placed on recently published papers that will alter practice in the therapeutic arena as well as discoveries in the basic sciences that have or will have clinical implications. Special attention will be paid to new therapies for chronic liver disease not only for HCV but also other major causes of chronic liver disease, including primary biliary cholangitis. Important changes in organ allocation that will impact the management of patients with advanced liver disease who are under the care of referring gastroenterologists will be highlighted as well as interventions to mitigate the major complications of cirrhosis.

Clinical Symposia

The Hospitalized Cirrhotic: Evidence-Based Management
Monday, May 8, 8:00 am – 9:30 am

Complications of portal hypertension are the major cause of morbidity and mortality and leading reason for hospitalization in patients with cirrhosis. These nclude encephalopathy, refractory ascites, variceal bleeding and renal dysfunction. Optimally recognizing these issues at an earlier stage of illness and proactive management willreduce hospitalizations and improve outcomes in cirrhotic patients. This symposium will focus on the interaction between portal hypertensive circulatory and renal changes and their complications and management. 

Best Practice: Management of HCC in 2017
Monday, May 8, 2:00 pm – 3:30 pm

The goal of this symposium is to provide an evidence-based update of the current management of HCC patients. This will include standard-of-care therapies and discussion of the recent clinical trials with novel approaches, such as Y90 or second line systemic agents.

New Concepts in the Assessment and Management of Alcoholic Liver Disease
Monday, May 8, 4:00 pm – 5:30 pm

Alcoholic liver disease is one of the leading causes of morbidity and mortality from  liver disease in the U.S. and the world. This program will cover three areas to help providers, including identifying and treating alcohol-use disorders, reviewing the treatment landscape, and exploring evolving indications for liver transplantation in alcoholic hepatitis.

Identification and Management of Patients with NAFLD and NASH
Tuesday, May 9, 8:00 am – 9:30am

The goals of this clinical program are to inform attendees on recent developments in the field of NAFLD, improving their ability to identify patients most in need of intervention and attention. It will also outline what can be done now that will positively impact their patients’ disease states and outcomes, as  well as therapies on the horizon holding great promise in changing the course of the disease.

Medical and Surgical Treatment of Portal Hypertension
Tuesday, May 9, 8:00 am – 9:30 am

This session will review the management of portal hypertension from a clinical viewpoint, including medical management, endoscopic therapy, radiological therapy and surgical options. Insights into up-and-coming possibilities relevant to the physicians who manage these patients will be discussed. In addition, a multidisciplinary panel of experts will offer their views on the topic and attendees will better understand the pros and cons of different therapeutic strategies and their indications in the management of portal hypertension.

Community Care of the Cirrhotic Patient
Tuesday, May 9, 10:00 am – 11:30 am

The symposium will focus on four of the most common issues facing community gastroenterologists: caring for patients with cirrhosis, the use and misuse of medications, the care of ascites in the setting of hyponatremia, and AKI and hypotension  and the medical legal implications of patients with HE with regards to driving motor vehicles.

Nutrition and Pediatric Liver Disease (co-provided with NASPGHAN)
Tuesday, May 9, 4:00 pm – 5:30 pm

Childhood health is traditionally assessed by well-paced growth and development, which is assured by adequate nutrition. Hence, chronic diseases that affect optimum nutritional intake, absorption and metabolism have the potential for significant impact on the health of the child. This symposium will allow the learner to understand the mechanisms involved in parenteral-nutrition-associated liver disease, the nutritional interventions required for patients with chronic cholestatic liver disease with undernutrition and the obese patient with overnutrition.

State-of-the-Art Lectures

NASH: Does My Liver Look Fat?
Sunday, May 7, 8:00 am – 9:00 am
Speaker: Zobair M. Younossi, MD, MPH, FAASLD

Upon completion of this activity participants will be able to:

  • Understand the comprehensive impact of NAFLD.
  • Understand the current state of biomarkers for NASH and fibrosis.
  • Understand the current state of treatment of NASH.

Hepatitis C: If One Pill Cures All, Why Aren’t All Patients Cured
Sunday, May 7, 10:00 am – 11:00 am
Speaker: Michael W. Fried, MD, FAASLD

Upon completion of this activity participants will be able to:

  • Understand the strengths and limitations of current direct acting antivirals for hepatitis C.
  • Identify baseline characteristics or comorbid conditions that can impact rates of response, such as resistance-associated polymorphisms, prior treatment experience, the presence of cirrhosis and the potential for drug-drug interactions.
  • Select appropriate treatments to optimize SVR across broad patient populations, including the treatment naïve and those who have failed prior DAA therapy.

DILI: Is this Pill Safe to Swallow?
Monday, May 8, 10:00 am – 11:00 am
Speaker: Paul B. Watkins, MD, FAASLD

Upon completion of this activity participants will be able to:

  • Better recognize drug-induced liver injury in patients.
  • Foresee changes in their practice that will be brought about by new blood tests in development.

Hepatitis B Treatment: Current Status and Prospects for Cure
Monday, May 8, 2:00 pm – 3:00 pm
Speaker: Anna S. Lok, MD, FAASLD

Upon completion of this activity participants will be able to:

  • Understand indications, efficacy and limitations of current HBV treatment.
  • Understand targets for new antiviral and immunomodulatory therapies.
  • Understand potentials and limitations for HBV cure and how to measure cure.